Lawsuit filed for Investors in shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) over alleged Securities Laws Violations

An investor, who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA), filed a lawsuitover alleged violations of Federal Securities Laws by Neumora Therapeutics, Inc. in connection with certain allegedly false and misleading statements made in connection with Neumora's September 2023 initial public offering (the "IPO").

Investors who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and for certain investors are short and strict deadlines running. Deadline: April 7, 2025. NASDAQ: NMRA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Watertown, MA based Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. In its IPO, Neumora sold 14.7 million shares at $17.00 per share. Neumora Therapeutics, Inc. (NASDAQ: NMRA) reported that its annual Total Revenue rose from $135.87 million in 2022 to $252.09 million in 2023, and that its Net Loss increased from $130.9 million in 2022 to $235.92 million in 2023.

On January 2, 2025, Neumora Therapeutics, Inc. revealed that the KOASTAL-1 study failed to "demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 or the key secondary endpoint of a change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) scale."

Shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) declined to as low as $1.55 per share on February 27, 2025.

The plaintiff claims that Offering Documents that were filed in connection with Neumora's September 2023 initial public offering contained false and/or misleading statements and/or failed to disclose that in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD, that and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD, and that the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Those who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.